Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

62.24
-2.3600-3.65%
Post-market: 63.501.26+2.02%19:59 EDT
Volume:1.58M
Turnover:99.30M
Market Cap:6.57B
PE:50.60
High:65.40
Open:64.60
Low:61.94
Close:64.60
Loading ...

Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
01 Nov 2024

Stock Track | Corcept Therapeutics Soars on Stellar Q3 Earnings and Upbeat Outlook

Stock Track
·
01 Nov 2024

Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Zacks
·
31 Oct 2024

Corcept Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
31 Oct 2024

Piper Sandler Remains a Buy on Corcept Therapeutics (CORT)

TIPRANKS
·
31 Oct 2024

Stock Track | Corcept Therapeutics Plunges on Study Concerns and Litigation Risks

Stock Track
·
31 Oct 2024

Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com
·
31 Oct 2024

Corcept Therapeutics Reports Strong Q3 Results and Positive Trial Outcomes

TIPRANKS
·
31 Oct 2024

Corcept Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary

Reuters
·
31 Oct 2024

Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates

Zacks
·
31 Oct 2024

Corcept: Q3 Earnings Snapshot

Associated Press Finance
·
31 Oct 2024

Stock Track | Corcept Stock Plummets After Hours Despite Solid Q3 Beat and Raised Guidance

Stock Track
·
31 Oct 2024

Corcept Therapeutics Reports Strong Revenue and Future Plans

TIPRANKS
·
31 Oct 2024

Corcept Therapeutics Inc Shares Down 14.7% After the Bell Following Results, Outlook

THOMSON REUTERS
·
31 Oct 2024

Corcept Therapeutics Sees 2024 Revenue $675M-$700M Vs $661.059M

Benzinga
·
31 Oct 2024

Corcept Therapeutics Q3 2024 GAAP EPS $0.41 Beats $0.28 Estimate, Sales $182.50M Beat $171.97M Estimate

Benzinga
·
31 Oct 2024

BRIEF-Corcept Therapeutics Q3 EPS USD 0.41 Vs. IBES Estimate USD 0.28

Reuters
·
31 Oct 2024

Corcept Therapeutics Inc - 2024 Revenue Guidance Raised to $675-$700 Million

THOMSON REUTERS
·
31 Oct 2024

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

Business Wire
·
31 Oct 2024

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

THOMSON REUTERS
·
24 Oct 2024